Kyle Mikson

Stock Analyst at Canaccord Genuity

(0)
# 4912
Out of 5,348 analysts
101
Total ratings
19.64%
Success rate
-26.49%
Average return
23 Stocks
Name Action PT Current % Upside Ratings Updated
AKYA Akoya Biosciences
Maintains: Hold
2 2
1.24 -12.9% 5 May 19, 2025
GRAL GRAIL
Maintains: Strong Buy
32 43
37.47 14.76% 2 May 14, 2025
BDSX Biodesix
Maintains: Buy
3 2
0.31 383.87% 4 May 14, 2025
XGN Exagen
Maintains: Strong Buy
7 8
7.14 12.04% 3 May 13, 2025
QTRX Quanterix
Maintains: Buy
15 12
5.24 129.01% 6 May 13, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
18 15
9.47 58.39% 8 May 12, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Hold
92 87
81.05 7.34% 10 May 12, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
42 37
16.2 128.4% 4 May 6, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Strong Buy
60 65
42.07 54.5% 6 May 1, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Hold
170 150
118.5 26.58% 3 Apr 16, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
3 3
0.99 203.03% 8 Apr 10, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Strong Buy
180 195
160.22 21.71% 8 Feb 28, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
3 3
1.26 138.1% 4 Nov 14, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Hold
2 1
1.68 -40.48% 3 Nov 13, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
95 75
56.07 33.76% 9 Nov 6, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Hold
3 5
n/a n/a 3 Jul 30, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Hold
26
n/a n/a 2 Mar 26, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
5 2
n/a n/a 4 Nov 27, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Hold
3
n/a n/a 4 Sep 25, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Overweight
3 2
0.52 284.62% 2 Aug 16, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Overweight
50
0.61 7965.57% 1 Mar 30, 2021
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Overweight
19
3.88 389.69% 1 Jan 29, 2021
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Overweight
150
n/a n/a 1 Jan 29, 2021